scPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest Down 36.1% in July

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

scPharmaceuticals, Inc. (NASDAQ:SCPH - Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 1,010,000 shares, adeclineof36.1% from the July 15th total of 1,580,000 shares. Currently,2.0% of the shares of the company are sold short. Based on an average daily volume of 357,200 shares, the short-interest ratio is currently 2.8 days. Based on an average daily volume of 357,200 shares, the short-interest ratio is currently 2.8 days. Currently,2.0% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of scPharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, scPharmaceuticals currently has an average rating of "Buy" and a consensus target price of $14.00.

Institutional Trading of scPharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of scPharmaceuticals by 63.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,336 shares of the company's stock worth $36,000 after acquiring an additional 3,628 shares during the period. Moss Adams Wealth Advisors LLC acquired a new stake in scPharmaceuticals during the second quarter valued at approximately $38,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in scPharmaceuticals during the second quarter valued at approximately $41,000. Walleye Capital LLC acquired a new stake in scPharmaceuticals during the second quarter valued at approximately $43,000. Finally, Assenagon Asset Management S.A. acquired a new stake in scPharmaceuticals during the first quarter valued at approximately $33,000. 89.52% of the stock is owned by institutional investors and hedge funds.

scPharmaceuticals Stock Performance

Shares of NASDAQ:SCPH traded up $0.28 during trading on Friday, reaching $4.85. The company had a trading volume of 289,254 shares, compared to its average volume of 332,399. The firm's fifty day moving average is $4.59 and its 200 day moving average is $3.57. scPharmaceuticals has a twelve month low of $1.94 and a twelve month high of $6.28. The company has a current ratio of 3.85, a quick ratio of 3.14 and a debt-to-equity ratio of 3.86.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.04). The company had revenue of $16.04 million during the quarter, compared to analyst estimates of $15.41 million. scPharmaceuticals had a negative return on equity of 1,647.86% and a negative net margin of 183.55%. Research analysts forecast that scPharmaceuticals will post -1.53 EPS for the current year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.